Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 2
1981 3
1983 2
1984 3
1985 1
1986 3
1987 4
1988 2
1989 3
1991 4
1992 3
1993 7
1994 5
1995 2
1996 4
1997 8
1998 3
1999 4
2000 5
2001 7
2002 11
2003 6
2004 2
2005 8
2006 10
2007 7
2008 12
2009 10
2010 9
2011 12
2012 14
2013 12
2014 11
2015 14
2016 14
2017 10
2018 10
2019 23
2020 38
2021 21
2022 31
2023 25
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Lung Small Cell Carcinoma"
Page 1
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR. Duma N, et al. Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. Mayo Clin Proc. 2019. PMID: 31378236 Review.
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. . …
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made …
Advances in systemic therapy for non-small cell lung cancer.
Miller M, Hanna N. Miller M, et al. BMJ. 2021 Nov 9;375:n2363. doi: 10.1136/bmj.n2363. BMJ. 2021. PMID: 34753715 Review.
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. ...
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past deca …
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y. Miao D, et al. Cancer Commun (Lond). 2024 Jan;44(1):23-46. doi: 10.1002/cac2.12505. Epub 2023 Nov 20. Cancer Commun (Lond). 2024. PMID: 37985191 Free PMC article. Review.
Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one-third of affected patients have locally advan …
Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non-small cell lung …
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
IMPORTANCE: Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient. OBJECTIVE: To investigate the status of biomarker testing and drug therapy for NSCLC in Japan for ident …
IMPORTANCE: Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (N …
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted th …
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell …
A rare bladder cancer--small cell carcinoma: review and update.
Ismaili N. Ismaili N. Orphanet J Rare Dis. 2011 Nov 13;6:75. doi: 10.1186/1750-1172-6-75. Orphanet J Rare Dis. 2011. PMID: 22078012 Free PMC article. Review.
Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and diagnosed mainly at advanced stages. ...The origin of the disease is unknown; however the multipotent stem cell theory applies best to this case. Histology and immunohistochemist …
Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and diagnosed mainly at advanced stages. ...The o …
Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review.
Baldini E, Tibaldi C, Delli Paoli C. Baldini E, et al. Clin Transl Oncol. 2020 Oct;22(10):1681-1686. doi: 10.1007/s12094-020-02326-6. Epub 2020 Mar 4. Clin Transl Oncol. 2020. PMID: 32128671 Review.
Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15-17% of these tumors are unresectable at presentation. ...We reviewed the available literature in order to report the state of art of stage III N …
Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15-17% of thes …
Management of centrally located non-small-cell carcinoma.
Backhus LM, Wood DE. Backhus LM, et al. Oncology (Williston Park). 2014 Mar;28(3):215-21. Oncology (Williston Park). 2014. PMID: 24855729 Free article. Review.
Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient selection. ...Therefore, other modalities are often necessary to complete the clinical staging. In the absence of irrefutable evidence of …
Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient s …
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Melosky B, et al. Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.
Lung cancer resulted in an estimated 1.8 million deaths worldwide in 2018 and approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III unresectable disease. ...A thorough review of the efficacy and safet …
Lung cancer resulted in an estimated 1.8 million deaths worldwide in 2018 and approximately 20% of patients with non-small …
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM. Aggarwal C, et al. Lung Cancer. 2021 Dec;162:42-53. doi: 10.1016/j.lungcan.2021.09.003. Epub 2021 Sep 15. Lung Cancer. 2021. PMID: 34739853 Free article. Review.
Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing i …
Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted t …
359 results